Z-360, a novel therapeutic agent for pancreatic cancer, prevents up-regulation of ephrin B1 gene expression and phosphorylation of NR2B via suppression of interleukin-1 β production in a cancer-induced pain model in mice

Z-360, a novel therapeutic agent for pancreatic cancer, prevents up-regulation of ephrin B1 gene expression and phosphorylation of NR2B via suppression of interleukin-1 β production in a cancer-induced pain model in mice

<p>Abstract</p> <p>Background</p> <p>Z-360 is an orally active cholecystokinin-2 (CCK2)/gastrin receptor antagonist currently under development as a therapeutic drug for pancreatic cancer. It was previously reported that Z-360 treatment in combination with gemcitabine p...

Full description

Bibliographic Details
Main Authors: Hori Yuko, Hamano Hiroki, Yoshinaga Koji, Kobayashi Nobuyoshi, Seto Koichi, Kato Hiroki, Orikawa Yuki, Meyer Tim, Takei Mineo
Format: Article
Language:English
Published: SAGE Publishing 2010-10-01
Series:Molecular Pain
Online Access:http://www.molecularpain.com/content/6/1/72

Internet

http://www.molecularpain.com/content/6/1/72

Similar Items